<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618122</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-GEN-TRA-001</org_study_id>
    <nct_id>NCT02618122</nct_id>
  </id_info>
  <brief_title>A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in Greece</brief_title>
  <acronym>beYOND-STS</acronym>
  <official_title>A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and the Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in Advanced Soft Tissue Sarcomas in a Real World Setting in Greece. The 'beYOND-STS' Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genesis Pharma S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genesis Pharma S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional study aims primarily at assessing the clinical effectiveness and the&#xD;
      impact of the therapy on cancer-related symptoms and patients' HRQoL. In addition, it&#xD;
      represents an attempt towards gaining experience on the routine use of trabectedin in daily&#xD;
      clinical practice in a representative sample of Greek subjects with aSTS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">August 6, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients that are alive and progression-free (as per the RECIST v1.1 criteria) 6 months after treatment commencement.</measure>
    <time_frame>6 months post-treatment onset</time_frame>
    <description>The proportion of patients that are alive and progression-free (as per the RECIST v1.1 criteria) 6 months after treatment commencement</description>
  </primary_outcome>
  <enrollment type="Actual">63</enrollment>
  <condition>Advanced Soft Tissue Sarcoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with a histologically confirmed diagnosis of advanced (locally advanced or&#xD;
        metastatic) soft tissue sarcoma who have failed treatment with anthracyclines and&#xD;
        ifosfamide or who are unsuited to receive these drugs&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients eligible for inclusion in this study have to meet all of the following criteria:&#xD;
&#xD;
          -  Adult outpatients (18 years and older) of either gender;&#xD;
&#xD;
          -  Patients with a histologically confirmed diagnosis of advanced (locally advanced or&#xD;
             metastatic) soft tissue sarcoma who have failed treatment with anthracyclines and&#xD;
             ifosfamide or who are unsuited to receive these drugs;&#xD;
&#xD;
          -  Patients for whom the decision to prescribe therapy with trabectedin (YondelisÂ®)&#xD;
             according to the locally approved product's summary of product characteristics (SmPC)&#xD;
             has already been taken prior to their enrolment in the study and is clearly separated&#xD;
             from the physician's decision to include the patient in the current study;&#xD;
&#xD;
          -  Patients must be able and willing to provide written informed consent and to comply&#xD;
             with the requirements of this study protocol;&#xD;
&#xD;
          -  Patients must have signed an informed consent document;&#xD;
&#xD;
          -  Patients must be able to read, understand and complete the study specific&#xD;
             questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A patient who meets any of the following criteria will be excluded from participation in&#xD;
        this study:&#xD;
&#xD;
          -  Patients who have received more than one cycle of trabectedin at the time of enrolment&#xD;
             into the study;&#xD;
&#xD;
          -  Patients that meet any of the contraindications to the administration of the study&#xD;
             drug according to the approved SmPC;&#xD;
&#xD;
          -  Patients who currently receive treatment with any investigational&#xD;
             drug/device/intervention or have received any investigational product within 1 month&#xD;
             or 5 half-lives of the investigational agent (whichever is longer) before the&#xD;
             commencement of therapy with trabectedin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiki Karvounis</last_name>
    <role>Study Director</role>
    <affiliation>GenesisPharma Medical Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 25, 2015</study_first_submitted>
  <study_first_submitted_qc>November 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

